



## **Amgen Named One of Fortune Magazine's '100 Best Companies to Work For'**

December 29, 2003

THOUSAND OAKS, Calif., Dec. 29 -- Amgen Inc. (Nasdaq: AMGN), the world's largest biotechnology company, today announced that it has been named by Fortune Magazine as one of the "100 Best Companies To Work For." This year, Amgen is honored to be ranked number 33. This is the fifth time the company has been on the list.

"We have long been convinced that investing in our staff and nurturing a patient-focused, values-based working environment is a key part of our ongoing success," said Kevin Sharer, Amgen's Chairman and Chief Executive Officer. "We strive to make Amgen a challenging, satisfying and rewarding place to work, and we are honored to be recognized by Fortune's annual list of '100 Best Companies To Work For.'"

Amgen is committed to providing a motivating work environment -- one that enables staff to make scientific breakthroughs and discoveries that improve the lives of others. Amgen's primary purpose is to use science and innovation to dramatically improve people's lives, and that mission serves as a motivator for Amgen staff throughout the organization.

In addition, the company currently offers a comprehensive compensation and benefits package that includes base salary, a performance-based bonus plan and stock option program, significant company contributions to employees' retirement savings accounts, medical, dental and vision insurance, and opportunities for career development. The company provides fitness centers in select locations and a stipend for private memberships in alternate locations, up to \$10,000 per year in tuition reimbursement, paternity leave, adoption aid, and numerous company events. At its headquarters, Amgen offers childcare and on-site conveniences including car wash, rental car services, dry cleaning, massage services, and a weekly farmer's market.

### About Amgen

Amgen is a global biotechnology company that discovers, develops, manufactures and markets important human therapeutics based on advances in cellular and molecular biology.

CONTACT: Amgen, Thousand Oaks

Media: (805) 447-4587

NOTE TO EDITORS: An electronic version of this news release may be accessed via our Web site at [www.amgen.com](http://www.amgen.com). Journalists and media representatives may sign up to receive all news releases electronically at the time of announcement by filling out a short form in the Media section of the Web site.